Application of Baricitinib in Dermatology
Open Access
- 1 March 2022
- journal article
- review article
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 15, 1935-1941
Abstract
There are four JAK subtypes: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). Small molecule Janus tyrosine kinase (JAK) inhibitors can inhibit a variety of pro-inflammatory cytokines. Baricitinib is the first generation of JAK1/2 inhibitor targeting the ATPase of JAK, which blocks the intracellular transmission of cytokines through JAK-STATs. Thus far, it has been approved for the treatment of rheumatoid arthritis (RA); however, an increasing number of studies have suggested that baricitinib can be used to treat dermatological diseases, such as atopic dermatitis (AD), psoriasis, vitiligo, and alopecia areata. Baricitinib can be a new choice for the treatment of dermatological diseases, which cannot be treated with conventional drugs. We reviewed the application, efficacy, side effects, precautions, limitations and prospect of baricitinib in atopic dermatitis, psoriasis, vitiligo and alopecia areata (AA) in recent 5 years including clinical trials and case reports. Among them, the application in the field of alopecia areata is the most encouraging, and we reviewed the mechanism in detail.Keywords
This publication has 38 references indexed in Scilit:
- JAK inhibitors in dermatology: The promise of a new drug classJournal of the American Academy of Dermatology, 2017
- Alopecia areataNature Reviews Disease Primers, 2017
- Baricitinib: First Global ApprovalDrugs, 2017
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasisBritish Journal of Dermatology, 2016
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor BaricitinibEBioMedicine, 2015
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic InterventionAnnual Review of Medicine, 2015
- British Association of Dermatologists’ guidelines for the management of alopecia areata 2012British Journal of Dermatology, 2012
- Alopecia AreataNew England Journal of Medicine, 2012
- Genome-wide association study in alopecia areata implicates both innate and adaptive immunityNature, 2010
- Signaling through the JAK/STAT pathway, recent advances and future challengesGene, 2002